Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Advancements to Educate About Innovations in Breach Detection Technology


Discover the latest breakthroughs in cybersecurity taking place today.

JUPITER, Fla., Aug. 11, 2023 /PRNewswire-PRWeb/ — An upcoming episode of Advancements with Ted Danson will focus on improvements in proactive cybersecurity technology.

The show will explore how current cybersecurity technologies react to threats and their effects after breaches happen. Audiences will learn about the importance of developing technologies that can remove exploits before breaches occur, to prevent and protect users from existing exposure.

With a look at Introspective Networks, viewers will see how recent developments in technology are working to protect networks by removing attack vectors. Spectators will see how its flagship technology, SmokeNet, uses a proactive approach to find and remove existing network vulnerabilities.

“Cybersecurity was not a concern when ARPANET, the network that eventually became the Internet, was developed in the 1970’s and 80’s. The main concern was diagnosing issues with the network and protocols. Those diagnostic capabilities have now been weaponized. The other issue was a quest for lawful intercept when the Internet first came online as the World Wide Web. Those attempts at intercept were clumsy and designed by politicians (CALEA law) and bureaucrats at the DOJ. There are two pieces of information required by those two things: an IP address and originating port. Our technology takes the known port away. We do something similar with encryption,” said Anthony Scott Thompson, Founder, Introspective Networks.

The show will also uncover how the technology isolates data transmission from the underlying network protocols to create a zero-trust architecture that protects data and systems from prevalent cybersecurity threats by removing direct use of, or trust in, the protocols on the Internet.

“Proactive cybersecurity requires a new way of thinking. We look forward to sharing how technology is creating a novel way to look at both the network and the root cause of cyber breaches, so problems can be solved before becoming serious issues,” said James Patterson, producer for the Advancements series.

About Introspective Networks:
Introspective Networks is a wholly owned subsidiary of Introspective Power, Inc. (IPi), a Delaware C-Corp doing business in Colorado at: 11001 W. 120th Ave. #400, Broomfield, CO 80020.

For more information, visit: https://inets.us/.

About Advancements and DMG Productions:
Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.

For more information, please visit http://www.AdvancementsTV.com or call 866-496-4065.

Media Contact

Sarah McBrayer, DMG Productions, 866-496-4065, info@advancementstv.com

SOURCE Advancements with Ted Danson

NetActuate Releases the 8th Generation of its Platform, Offering Streamlined, Intuitive Management of Complex Global Deployments


NetActuate has just released the 8th generation of its infrastructure and network management platform. This new version includes a number of user enhancements, such enhanced API(s), as well as simple, seamless self-service control over large global deployments and BGP anycast networking.

RALEIGH, N.C., Aug. 11, 2023 /PRNewswire-PRWeb/ — NetActuate, a leading provider of global infrastructure and network services, has announced today the release of the eighth generation of its global platform. Existing customers can now experience powerful new features for streamlined self-service management of their global deployments.

The new release builds on NetActuate’s years of experience operating self-service cloud and networking platforms. The eighth version incorporates an intuitive, robust UI that enables greater insight and visibility across a range of infrastructure and network services. From virtual servers to bare metal and colocation, the new platform allows for easier monitoring and optimization, as well as greater self-service options than ever before.

“We couldn’t be prouder of the work done by our development and engineering teams to deliver the eighth generation of our platform,” said Mark Mahle, CEO of NetActuate. “From the data center up, we have always had full control over our entire stack. This allows us to innovate at all levels to deliver numerous improvements for our customers.”

Inside the new platform, users can intuitively and easily manage their entire global deployment. From spinning up new virtual servers, to monitoring bandwidth in the data center, NetActuate customers now have more control than ever before, right at their fingertips.

“Unlike other companies in this space, NetActuate is truly engineering-led,” said Mark Price, Vice President of Infrastructure. “Our development and engineering teams worked hand-in-hand to rework the entire platform experience for end users, and add in powerful new capabilities wherever we could.”

Anycast customers now have powerful new tools for node management. From adding and removing locations instantly, to enabling them to see their entire anycast network at-a-glance, network optimization is now easier than ever.

To learn more about NetActuate’s platform and services, you can schedule a discovery call with an engineer today at netactuate.com.

About NetActuate
NetActuate is a leading provider of highly available, low latency custom network and infrastructure services that reach every major global market. From the datacenter to the last mile, we help providers take their products and services to the global edge faster. Our customers can rapidly scale without fear of high costs or devastating performance issues. We built one of the world’s largest global networks by number of peers, and it serves as the foundation for our performance BGP anycast platform that powers over 25 billion transactions a day.

To schedule a call with NetActuate engineers or learn more about our products and services, visit netactuate.com. To discover how anycast can boost reliability, reduce latency, and simplify architecture all at the network level, visit NetActuate’s anycast resource site at anycast.com.

Media Contact

Marketing Director, NetActuate, +1.919.381.5400, [email protected]

LinkedIn

SOURCE NetActuate

Rare Disease Trials and Gene Therapy: Understanding the Patient…


In this free webinar, gain insights into addressing challenges to operationalizing a gene therapy trial such as manufacturing, patient recruitment, site selection and activation, and regulatory…

(PRWeb June 29, 2023)

Read the full story at https://www.prweb.com/releases/rare_disease_trials_and_gene_therapy_understanding_the_patient_journey_upcoming_webinar_hosted_by_xtalks/prweb19418196.htm

Revolutionizing Cell and Gene Therapy Trials with Human-Centered…


In this free webinar, learn about the true potential of study companion apps, redefining the intricate realm of cell and gene therapy trials and fostering meaningful patient experiences in the world…

(PRWeb June 29, 2023)

Read the full story at https://www.prweb.com/releases/revolutionizing_cell_and_gene_therapy_trials_with_human_centered_design_and_real_patient_narratives_upcoming_webinar_hosted_by_xtalks/prweb19418260.htm

Effectively Balancing Design, Schedule, and Budgets, Upcoming Webinar Hosted by Xtalks


From the perspective of laboratory managers, a successful facility design project may be defined as a lab that meets all present and future required functionalities. On the other hand, capital project managers could interpret success as a lab design that adheres to a predefined budget and timeline.

A new enlightening webinar is set to take place, shedding light on the complexities of laboratory design and project management, under the title “Successful Lab Projects: Effectively Balancing Design, Schedule, and Budgets.”

From the perspective of laboratory managers, a successful facility design project may be defined as a lab that meets all present and future required functionalities. On the other hand, capital project managers could interpret success as a lab design that adheres to a predefined budget and timeline.

Navigating between the competing interests of laboratory management and capital project management often presents challenges during the lab design phase. The upcoming webinar addresses these challenges by exploring key steps to ensure successful projects for all stakeholders.

Two distinguished speakers will lead this insightful discussion. Jim Schreyer, a Senior Project Manager at Hixson, brings his extensive experience in managing projects of various scales, from $2 million to $150 million, for science and technology and GMP manufacturing projects across North America. Alongside him, Paul Thamann, a Senior Project Architect at Hixson, brings nearly two decades of architectural project leadership and direct client interaction. In addition, Paul also serves as the Lead for Hixson’s Science & Technology (S&T) Strategic Business Unit.

Hixson is a well-recognized firm partnering with world-renowned brands on complex science + technology, workplace and food and beverage projects. As one of the top firms in the United States, Hixson consistently provides insight, advocacy, and intelligent project execution through its 20 integrated in-house design and technical disciplines.

In alliance with Xtalks, Hixson continues to bring valuable knowledge to the forefront through this webinar. The partnership between Hixson and Xtalks aims to provide a platform for knowledge sharing and innovation in the field of laboratory design and management.

Mark your calendars for the free, live webinar, which will take place on Tuesday, July 18, 2023, at 2pm EDT (11am PDT).

For more information, or to register for this event, visit Successful Lab Projects: Effectively Balancing Design, Schedule, and Budgets.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Unleash the Power of Artificial Intelligence, Upcoming Webinar Hosted by Xtalks


Touchless case processing, an emerging practice that eliminates the need for manual intervention, is set to bring about next-level efficiency gains in pharmacovigilance.

In the life sciences industry, the pressure is on as pharmacovigilance teams grapple with growing case volumes and stagnant budgets; however, innovative solutions are emerging that can help these teams maximize efficiency and demonstrate value.

One such innovation is the application of artificial intelligence (AI) and machine learning (ML) in pharmacovigilance. These technologies promise to revolutionize case processing by automating tedious, error-prone tasks and increasing efficiency and accuracy. Touchless case processing, an emerging practice that eliminates the need for manual intervention, is set to bring about next-level efficiency gains in pharmacovigilance.

To shed light on these promising developments, a transformative, free webinar is scheduled for industry professionals. Titled “Best Practices in Pharmacovigilance: Unleash the Power of Artificial Intelligence”, the webinar will cover how pharmacovigilance teams can leverage enhanced automation to accelerate case intake, provide greater consistency and reliability and pave the way for the future of patient safety.

This enlightening webinar will be led by Christina Barker, Sr. Director of Product Management, Safety/AIML at ArisGlobal, who has over three decades of experience in the life sciences domain, and Emmanuel Belabe, Vice President of Solution Consulting at ArisGlobal, who has spent 17 years with the company in various roles, making significant contributions in multiple R&D domains.

The live webinar is taking place on Wednesday, July 19, 2023, at 11am EDT (4pm BST/UK) and is a collaborative effort between ArisGlobal and Xtalks.

For more information, or to register for this event, visit Best Practices in Pharmacovigilance: Unleash the Power of Artificial Intelligence.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Persist AI Adopts Scispot to operate as a Digital Biotech company


Scispot — The Best Tech Stack for Modern Biotech

“As an AI-focused biotech company, digitizing and automating our processes from the get-go has been imperative. Scispot has been instrumental in establishing the right digital foundation to achieve this objective.”

Scispot, the creator of the best tech stack for modern biotech, announces that Persist AI, an AI-driven biotech company specializing in the creation of long-acting microsphere formulations, has selected them to provide a robust data infrastructure. This partnership aims to automate Persist AI’s research workflows and scale its AI capabilities. Persist AI is currently utilizing Scispot as its primary data and workflow management platform, effectively gathering and integrating data from diverse sources, thereby optimizing its use in machine learning and artificial intelligence processes.

Persist AI is committed to slashing drug formulation development time by 50% to just 2 years through the power of AI-driven automation. Traditional methods would typically see pharmaceutical companies investing approximately five years to develop long-lasting drug formulations. However, with Persist AI’s integration of advanced AI automation, the process is accelerated, targeting a 50% reduction in overall development time. Using Scispot’s flexible platform, Persist AI is geared towards designing long-lasting injections that allow for slow drug release over prolonged periods. The AI models, trained using patterns extrapolated from a range of experiments, predict drug release rates and enhance formulation efficiency. This game-changing approach is set to revolutionize patient experience and adherence to treatments.

“As an AI-focused biotech company, digitizing and automating our processes from the get-go has been imperative. Scispot has been instrumental in establishing the right digital foundation to achieve this objective,” stated Karthik Raman, Founder & CEO of Persist AI. “Scispot organizes not just experimental, but also organizational data, optimizing resource utilization. With the aid of Scispot’s robust data management system, we have been able to connect our in silico data with the automated experiments we perform in the real world and to track resources like lab materials which are utilized in each batch.”

“We at Scispot feel a deep synergy with Persist AI’s objective, which resonates with our mission of reducing the time it takes to bring new drugs to market,” stated Guru Singh, Founder & CEO of Scispot. “We strive to empower modern biotech companies with our advanced data infrastructure, supporting their transformation into full-fledged Digital Biotech entities. Persist AI epitomizes this transformation, and we are thrilled to support their commitment to delivering life-saving solutions more rapidly to the marketplace.”

Persist AI’s digital transformation journey with Scispot has yielded substantial enhancements in their research and development processes. Formerly dependent on Excel and Google Sheets, Persist AI required a solution capable of efficiently accommodating their growing demands, all while preserving comprehensive versioning and data integrity. Scispot’s extensive capabilities have established a centralized hub, negating the necessity to manage numerous Excel sheets and facilitating smooth permissions for team members. The implementation of Scispot has led to improved organization, streamlined procedures, and automated data management.

As the digital era evolves, Scispot has secured its position as the tech stack of choice for modern biotech companies, particularly those focusing on machine learning and artificial intelligence. With its API-friendly electronic lab notebook (ELN) and lab information management system (LIMS), Scispot expertly marshals all R&D data. This strategic approach paves the way for smooth integration with advanced machine learning and AI, enabling companies to expedite their path to groundbreaking innovations.

ABOUT SCISPOT

Scispot is a Y Combinator-backed life science informatics company based in the Kitchener-Waterloo and Seattle area. Scispot has created the best tech stack to help modern biotechs evolve into efficient, scalable TechBio companies. Scispot’s toolkit makes biotech R&D templatizable and programmable, enabling companies to automate lab management, centralize data, establish repeatable workflows, and comply with regulatory guidelines. To learn more, please visit http://www.scispot.com.

ABOUT PERSIST AI

Persist AI is a pioneering biotech company using artificial intelligence and machine learning to drastically expedite the development of long-acting, extended-release drug formulations. With a commitment to reducing traditional development time by 50%, Persist AI enables pharmaceutical manufacturers to optimize drug loading, morphology, and distribution, delivering solutions in weeks instead of years. Persist AI’s innovative approach is revolutionizing the treatment of chronic conditions such as cancer and diabetes by significantly accelerating the drug formulation process. To learn more, please visit http://www.persist-ai.com.

Share article on social media or email:

Chacruna Publishes Article Challenging DEA Ayahuasca Report


It is clear that the DEA’s stance on ayahuasca does not find support in scientific evidence. This could be seen as an attempt to curtail minority religious rights in the United States. – Henrique Antunes, PhD, Ayahuasca Community Coordinator, Chacruna Institute

In February 2023, the Drug Enforcement Administration (DEA) released a document to the legal team representing the Church of the Eagle and the Condor (CEC). This disclosure came two years after the CEC and the Chacruna Institute for Psychedelic Plant Medicines submitted two FOIA requests to the DEA and the Department of Justice requesting all records pertaining to ayahuasca.

The report, titled “Ayahuasca: Risks to Public Health and Safety,” was issued in July 2020. It takes a very clear stance against the use of ayahuasca, claiming that it presents a significant risk to public health and safety. According to contributors from the Chacruna Institute, the report is in line with the prohibitionist approach of the US government, which has continued to target ayahuasca groups through seizures, arrests and other actions. The report is also a strong indication that the government will be resistant to recognizing religious minorities and traditional populations’ rights.

On June 9, 2023, the Chacruna Institute published an article in the peer-reviewed Journal of Psychedelic Studies contesting the DEA’s report. The article, “The DEA Report on Ayahuasca Risks: ‘Science’ in Service of Prohibition?” was written in partnership with leading experts on ayahuasca, including scholars from the fields of biology, neuroscience, psychology, psychiatry, anthropology, and sociology.

The article challenges a number of assertions made by the DEA, highlighting significant factual omissions, theoretical biases, and misinterpretations of existing data. The article highlights how the DEA report severely downplays the safety profile and therapeutic potential of ayahuasca, ignores a vast body of epidemiological evidence from its use among Indigenous and religious communities around the world, and overemphasizes the risks, while failing to include current research on ayahuasca demonstrating its potential benefits.

Chacruna Institute members assert that this shows that the prohibitionist paradigm and the persecution of ethnic and religious minorities will not be ignored and that the global scientific community is taking a stand against the criminalization of ayahuasca. If you want to read the full critique of the DEA’s report, click here: https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2023.00279/article-10.1556-2054.2023.00279.xml?body=fullhtml-26185. To support this kind of critical psychedelic scholarship, please consider donating to support Chacruna’s mission.

About Chacruna Institute

The Chacruna Institute for Psychedelic Plant Medicines, is a 501(c)(3) non-profit organization co-founded by Brazilian anthropologist Dr. Bia Labate and American psychologist Dr. Clancy Cavnar, based in Northern California and with strong ties to Brazil and Mexico. We promote reciprocity in the psychedelic community, and support the protection of sacred plants and cultural traditions. We advance psychedelic justice through curating critical conversations and uplifting the voices of women, queer people, Indigenous peoples, people of color, and the Global South in the field of psychedelic science.

Share article on social media or email:

A New Book, THE LIGHT DOCTOR, Reveals the Health Hazards of LED Light, and Advises on the Lights You Need to Protect Your Health


News Image

THE LIGHT DOCTOR by Dr. Martin Moore-Ede

“The light we see is as important to our health as the air we breathe, the food we eat, and the water we drink. THE LIGHT DOCTOR shows you how to take charge of the light you see and avoid using harmful and unhealthy LED and fluorescent lights,” said Martin Moore-Ede.

Not all light is healthy. Nowadays we spend more than 90% of our time indoors, under unhealthy and human-unfriendly electric light, which disrupts circadian clocks and greatly increases the risk of cancer, obesity, diabetes, heart disease and hundreds of other diseases. In his newest book, THE LIGHT DOCTOR, Dr. Moore-Ede, a leading world expert on circadian clocks and the brain, and on the health problems caused by electric light, reveals the extensive scientific evidence that establishes the risks of artificial light at night and how to make the right lighting choices.

  • The science on LED light is extensive, and the risks well established, yet most people are largely unaware of the risks to their health from artificial light.
  • By 2007, the first 10,000 scientific studies of the impact of light on circadian clocks led a World Health Organization agency to classify light at night as a possible carcinogen.
  • In 2021, another 10,000 scientific publications later, the NIH’s National Toxicology Program identified the culprit – excessive blue-rich light at night (and insufficient blue daylight exposure), which is delivered by today’s LED and fluorescent lights.


Today’s LED and fluorescent lights are designed for energy efficiency with little regard for human health. Like DDT and asbestos, static blue-rich lights are a dangerously flawed technology. In addition to his engaging explanations of the science of light, Dr. Moore-Ede provides the practical information people need to counteract these risks at home, in business and medical offices, and in public spaces, hospitals, and care facilities.

“THE LIGHT DOCTOR…terrified me, in the best way. Dr. Moore-Ede is doing cutting-edge work to change the way we think about light and how it affects us.” Penguin Life

“I was so impressed with his detailed yet thoroughly comprehensible explanations and expert advice! I’ll definitely be changing some of my light bulb’s ASAP!” Simon Element

“Whether you are a healthcare worker spending long hours on the floor, have a child in a classroom, or are a senior enjoying the comforts of home, everyone needs to know which lights and display screens disrupt their circadian clocks and can cause sleep disorders, depression, obesity, diabetes, heart disease, and breast cancer. They also need to know where to find the lights and display screens that will boost their health and performance as an essential part of a healthy lifestyle,” said Dr Moore-Ede.

The LIGHT DOCTOR explains not only the science behind healthy and unhealthy lighting, but also provides a practical guide to the lights and display screens people should be buying to keep themselves, as well as family and friends, safe and healthy. The book details how to find and install healthy light bulbs and fixtures for both residential and commercial space; how to obtain the lights, and display screens, needed for evening and night use versus daytime; and how to obtain energy efficient light that is also safe and healthy. Also, you will learn which outdoor lights to install to avoid harmful effects on wildlife, another inadvertent consequence of the LED revolution.

Dr. Moore-Ede brings a unique perspective from the forefront of the battle against unhealthy lights. While a professor at Harvard Medical School, he discovered the location of the circadian clock in the human brain and how it is synchronized by light. As a consultant to over 50% of the Fortune 500 companies, he has seen first-hand the harmful effects of light at night in the real world. His discovery of the narrow sky-blue signal that synchronizes circadian clocks led to the invention and patenting of evidence-based circadian lighting and the demonstration of its effectiveness in many major companies.

“The light we see is as important to our health as the air we breathe, the food we eat, and the water we drink. THE LIGHT DOCTOR shows you how to take charge of the light you see and avoid using harmful and unhealthy LED and fluorescent lights,” said Moore-Ede.

Readers may ask themselves:

  • What type of light causes the most health risks?
  • Can I use the same lightbulb during the day and evening?
  • How do I make sure I have healthy lights in my home?
  • Can I tell how much blue is in a light by looking at it?
  • Why does the Department of Energy promote harmful lights?
  • What daily lifestyle 14 can I make to improve my health?
  • How do I protect my children from harmful blue light?


The book is written for anyone interested in living a healthier life with the correct lighting. The information provided in this book is backed by a recent survey of 248 scientists by the Circadian Light Research Center, led by Moore-Ede. In it, the scientists, who have collectively published 2,697 peer-reviewed scientific articles on circadian clocks and light, confirmed that human circadian clocks are highly sensitive to blue wavelengths, and exposure to insufficient daytime blue-rich light and excessive blue-rich light at night, leads to many major health disorders.

The LIGHT DOCTOR is being released on Substack, debuting June 14, 2023. People may sign up for a free subscription at https://lightdoctormartinmooreede.substack.com to read the first three chapters. With a free subscription to THE LIGHT DOCTOR, people can view the initial chapters without charge. Then if they like what you see and want to learn more, the paid subscription costs $5 per month or $30 for annual subscription.

A new chapter will be released at two-weekly intervals. In the intervening weeks Dr. Moore-Ede will provide other supporting information and respond to comments and questions.

About Martin Moore-Ede M.D., Ph.D.

For over 40 years, Dr. Moore-Ede has been a leading world expert on circadian clocks and the health problems caused by electric light at night. As a professor at Harvard Medical School (1975 – 1998), he led the team that located the suprachiasmatic nucleus, the biological clock in the human brain that controls the timing of sleep and wake. He pioneered research on how circadian clocks regulate the timing of body functions. Since 2010, he has led the Circadian Lighting Research Center team that identified the key blue signal that synchronizes circadian clocks and developed patented LED lights, which provide circadian-optimized light across day and night based on comprehensive medical research. The effectiveness of these circadian-modulated lights in improving health and well-being has been validated by installing them in the 24-hour operations of Fortune 500 companies and hospitals. He has published over 180 scientific articles and authored ten books, including the best-selling books, The Clocks that Time Us, and The Twenty-Four Hour Society and he is now releasing on Substack his new book: The Light Doctor: The Science and Solutions for Replacing Your Lights Now to Protect Your Health. For more information visit, https://lightdoctormartinmooreede.substack.com LinkedIn, Twitter, Instagram and https://thelightdoctor.com/

Share article on social media or email:

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors, Strengthening Expertise in Oncology and Precision Medicine


I am excited to become a member of the board of directors at PredxBio, a company with immense potential to revolutionize biomarker discovery and clinical research through its advanced spatial biology analytics.-Dr. Stanley Marks

PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.

“We are thrilled and privileged to welcome Dr. Marks as a distinguished member of PredxBio’s board of directors,” expressed Dusty Majumdar, PhD, CEO of PredxBio. “As a highly regarded pioneer in the field of oncology with extensive experience and a demonstrated history of visionary leadership in cancer care, Dr. Marks brings invaluable insights that will greatly contribute to our ongoing advancements at PredxBio.”

Dr. Stanley Marks, MD, holds the prestigious position of Chairman of UPMC Hillman Cancer Center, serving as the Chief of the Division of Hematology-Oncology at UPMC Shadyside, and a Clinical Professor of Medicine at the University of Pittsburgh. Dr. Marks was also honored by UPMC and his medical partners at Oncology Hematology Association (OHA) through the establishment of the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership. With a remarkable career in cancer research, Dr. Marks has held key leadership roles such as President of The Leukemia & Lymphoma Society and has been a member of the board of directors of the American Cancer Society, among others. Recognized as one of the “Best Cancer Doctors in America,” Dr. Marks is a highly respected clinician and a passionate advocate for patients. His impact is evident through the establishment of the Dr. Stanley Marks Research Endowed fund at the Hillman Cancer Center, which has raised an impressive $18 million for cancer research to date.

“I am excited to become a member of the board of directors at PredxBio, a company with immense potential to revolutionize biomarker discovery and clinical research through its advanced spatial biology analytics,” commented Dr. Marks. “PredxBio’s cutting-edge solutions offer scientists in the biopharma and health systems the ability to gain comprehensive and deep insights into the organization and interactions of cells within the tissue microenvironment. PredxBio’s promising results in understanding of disease progression and treatment response to immunotherapy demonstrate the transformative power of this technology.”

Welcoming Dr. Marks to PredxBio’s board of directors, D. Lansing Taylor, PhD, Chairman of the Board at PredxBio and Director at the University of Pittsburgh Drug Discovery Institute (UPDDI), remarked, “Dr. Mark’s deep experience in oncology and his leadership will be invaluable to PredxBio as we grow our business and pursue our mission to leverage the power of spatial biology with Explainable AI and unbiased spatial analytics in delivering innovative therapies that will positively impact the lives of patients.”

The PredxBio platform seamlessly integrates multimodal data, such as spatial proteomics, spatial transcriptomics, and brightfield pathology, to uncover the hidden circuitries of tumor microenvironments and reveal the complex network biology of cancer. By performing highly scalable, Explainable AI (xAI) powered spatial analyses of diverse imaging techniques, PredxBio generates actionable insights for biomarker discovery, identifying drug targets, and designing effective clinical trials. Through the quantification of cell-cell interactions, identification of intermediate cell types and states, and discovery of microdomains, PredxBio delves into the organizing principles of spatial intratumor heterogeneity, providing a mechanistic understanding of tumor initiation, progression, and response to therapy. This comprehensive platform drives personalized therapeutic options, improving prediction accuracies based on spatial tumor biology and enabling optimal treatment selection for individual patients. With the launch of the PredxBio platform, we established our leadership position in Spatial Biology, uniquely capable of predicting patient outcomes with 90%+ accuracy by unraveling the hidden biological circuitries of cancer.

About PredxBio

PredxBio is a Pittsburgh, PA-based company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio’s solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio’s solutions to assess treatment response in immunotherapy.

http://www.predxbio.com

Share article on social media or email: